Tumor Biology Hides Novel Therapeutic Approaches to Diffuse Large B-Cell Lymphoma: A Narrative Review DOI Open Access
Romana Masnikosa, Zorica Cvetković, David Pirić

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(21), P. 11384 - 11384

Published: Oct. 23, 2024

Diffuse large B-cell lymphoma (DLBCL) is a malignancy of immense biological and clinical heterogeneity. Based on the transcriptomic or genomic approach, several different classification schemes have evolved over years to subdivide DLBCL into clinically (prognostically) relevant subsets, but each leaves unclassified samples. Herein, we outline tumor biology behind actual potential drug targets address challenges drawbacks coupled with their (potential) use. Therapeutic modalities are discussed, including small-molecule inhibitors, naked antibodies, antibody-drug conjugates, chimeric antigen receptors, bispecific antibodies T-cell engagers, immune checkpoint inhibitors. Candidate drugs explored in ongoing trials diverse toxicity issues refractoriness drugs. According literature DLBCL, promise for new therapeutic lies epigenetic alterations, receptor NF-κB pathways. present putative hiding lipid pathways, ferroptosis, gut microbiome that could be used addition immuno-chemotherapy improve general health status patients, thus increasing chance being cured. It may time devote more effort exploring metabolism discover novel druggable targets. We also performed bibliometric knowledge-map analysis published from 2014-2023.

Language: Английский

Cytostatic Bacterial Metabolites Interfere with 5-Fluorouracil, Doxorubicin and Paclitaxel Efficiency in 4T1 Breast Cancer Cells DOI Creative Commons

Szandra Schwarcz,

Petra Nyerges,

Tı́mea Bı́ró

et al.

Molecules, Journal Year: 2024, Volume and Issue: 29(13), P. 3073 - 3073

Published: June 27, 2024

The microbiome is capable of modulating the bioavailability chemotherapy drugs, mainly due to metabolizing these agents. Multiple cytostatic bacterial metabolites were recently identified that have effects on cancer cells. In this study, we addressed question whether a set (cadaverine, indolepropionic acid and indoxylsulfate) can interfere with agents used in management breast (doxorubicin, gemcitabine, irinotecan, methotrexate, rucaparib, 5-fluorouracil paclitaxel). drugs applied wide concentration range which metabolite was added within its serum reference range, cell proliferation assessed. There no interference between methotrexate or rucaparib metabolites. Nevertheless, cadaverine modulated Hill coefficient inhibitory curve doxorubicin 5-fluorouracil. Changes implicate alterations kinetics binding their targets. These an unpredictable significance from clinical pharmacological perspective. Importantly, decreased IC50 value paclitaxel, potentially advantageous combination.

Language: Английский

Citations

2
Impact of Gut Microbiota on Lymphoma: New Frontiers in Cancer Research DOI
Sabri Saeed Sanabani

Clinical Lymphoma Myeloma & Leukemia, Journal Year: 2024, Volume and Issue: unknown

Published: Aug. 1, 2024

Language: Английский

Citations

2
Tumor Biology Hides Novel Therapeutic Approaches to Diffuse Large B-Cell Lymphoma: A Narrative Review DOI Open Access
Romana Masnikosa, Zorica Cvetković, David Pirić

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(21), P. 11384 - 11384

Published: Oct. 23, 2024

Diffuse large B-cell lymphoma (DLBCL) is a malignancy of immense biological and clinical heterogeneity. Based on the transcriptomic or genomic approach, several different classification schemes have evolved over years to subdivide DLBCL into clinically (prognostically) relevant subsets, but each leaves unclassified samples. Herein, we outline tumor biology behind actual potential drug targets address challenges drawbacks coupled with their (potential) use. Therapeutic modalities are discussed, including small-molecule inhibitors, naked antibodies, antibody-drug conjugates, chimeric antigen receptors, bispecific antibodies T-cell engagers, immune checkpoint inhibitors. Candidate drugs explored in ongoing trials diverse toxicity issues refractoriness drugs. According literature DLBCL, promise for new therapeutic lies epigenetic alterations, receptor NF-κB pathways. present putative hiding lipid pathways, ferroptosis, gut microbiome that could be used addition immuno-chemotherapy improve general health status patients, thus increasing chance being cured. It may time devote more effort exploring metabolism discover novel druggable targets. We also performed bibliometric knowledge-map analysis published from 2014-2023.

Language: Английский

Citations

1